Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Bodyweight gain with atypical antipsychotics. A comparative review.

Wetterling T.

Drug Saf. 2001 Jan;24(1):59-73. Review.

PMID:
11219487
2.

[Weight gain from atypical neuroleptics--an underreported adverse effect?].

Wetterling T.

Fortschr Neurol Psychiatr. 2000 Dec;68(12):546-56. Review. German.

PMID:
11200858
3.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
4.

[Atypical antipsychotic drugs].

Kahn RS.

Ned Tijdschr Geneeskd. 2000 Aug 19;144(34):1627-30. Review. Dutch.

PMID:
10972052
5.

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.

Kapur S, Remington G.

Annu Rev Med. 2001;52:503-17. Review.

PMID:
11160792
6.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
7.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
8.

Review of atypical antipsychotics and weight gain.

Sussman N.

J Clin Psychiatry. 2001;62 Suppl 23:5-12. Review.

PMID:
11603886
9.
10.

Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.

Potvin S, Stip E, Roy JY.

Int Clin Psychopharmacol. 2003 May;18(3):121-32. Review.

PMID:
12702890
11.

Use of atypical antipsychotics in mood disorders.

Weizman R, Weizman A.

Curr Opin Investig Drugs. 2001 Jul;2(7):940-5. Review.

PMID:
11757795
12.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
13.

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

Glazer WM.

J Clin Psychiatry. 2000;61 Suppl 3:16-21. Review.

PMID:
10724129
14.

The pharmacology of weight gain with antipsychotics.

Casey DE, Zorn SH.

J Clin Psychiatry. 2001;62 Suppl 7:4-10. Review.

PMID:
11346195
15.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
16.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2003;(1):CD001359. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD001359.

PMID:
12535408
17.

Risperidone versus other atypical antipsychotic medication for schizophrenia.

Gilbody SM, Bagnall AM, Duggan L, Tuunainen A.

Cochrane Database Syst Rev. 2000;(3):CD002306. Review.

PMID:
10908551
18.

[Clinical efficacy of olanzapine].

Yui K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 1999 Jul;19(3):101-10. Review. Japanese.

PMID:
10495984
19.
20.

Atypical antipsychotics and weight gain--a systematic review.

Taylor DM, McAskill R.

Acta Psychiatr Scand. 2000 Jun;101(6):416-32. Review.

PMID:
10868465
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk